Yea Christopher 4

4 · KalVista Pharmaceuticals, Inc. · Filed Feb 24, 2026

Form 4

Period: 2026-02-21

CHIEF DEVELOPMENT OFFICER

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-02-21+3,750→ 227,923 total
Exercise/Conversion
Common Stock
[F1]
2026-02-22+3,125→ 231,048 total
Sale
Common Stock
[F2][F3]
2026-02-23$15.57/sh−4,347$67,669→ 226,701 total
Exercise/Conversion
Restricted Stock Unit
[F1][F4]
2026-02-21−3,750→ 45,000 total
→ Common Stock (3,750 underlying)
Exercise/Conversion
Restricted Stock Unit
[F1][F4]
2026-02-22−3,125→ 28,125 total
→ Common Stock (3,125 underlying)

Footnotes (4)

[F1]Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
[F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
[F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.5182 to $15.566982 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through each vesting date.

Signature

/s/ Benjamin L. Palleiko, Attorney-in-Fact|2026-02-24

Documents

1 file